The European Medicines Agency has started a rolling review of a prospective vaccine for Covid-19 being developed by Oxford University and AstraZeneca Plc on the basis of preliminary data showing that it triggered the production of antibodies and T cells that target the virus. The agency announced the review on 1 October.
